The latest research report serves as a perfect example of the precise analysis of the global Recurrent Atrial Fibrillation market. It includes the ToC, list of tables and figures, research methodology, geographic segmentation, competitive landscape, future developments, and technological innovation. Moreover, the report offers the latest coverage of the massive impact of the COVID-19 pandemic on the worldwide Recurrent Atrial Fibrillation industry. The globally-disrupting incidence has impacted nearly every aspect of this business domain. However, the latest study expounds on the present market scenario and forecasts the pandemic’s aftermath, with respect to this industry. Furthermore, the major aspects of the market have been discussed in the report, with expert opinions on the current status of the market.
Key participants contributing significant market shares in the industry growth includes Johnson Johnson, Medtronic Plc, Abbott Laboratories, Microport Scientific Corporation, Atricure Inc., Boston Scientific Corporation, St. Jude Medical, Inc., Siemens AG, Koninklijke Philips N.V., AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, and GlaxoSmithKline.
Get a Free sample of the report : https://www.emergenresearch.com/request-sample/71
Factors driving this market include augmenting incidence rate of recurrent atrial fibrillation, new product launches for effective treatment of recurrent events, and improved reimbursement scenarios for recurrent AFib treatment drugs along with technological advancements are expected to become the most common growth factors globally in the coming years
The report is updated with the latest economic scenario and market scope with regard to the ongoing COVID-19 pandemic. The report covers growth prospects as well as current and futuristic revenue estimations in a post COVID scenario. The report also covers changing trends and market dynamics due to the pandemic and provides an accurate impact analysis of the crisis on the overall market.
Some Key Highlights from the Report
In January 2019, Abbott announced the acceptance of the TactiCath Touch Force Ablation Catheter by the FDA. Such winning tactics of leading companies in the market for atrial fibrillation products are often adopted by national and local companies.
The prevalence of AFib ranges between 2.7 million and 6.1 million in the U.S. alone and is estimated to reach 12.1 million by the year 2030, according to the statistics of the Center for Disease Control. Similar incidence rates are observed in other regions as well, indicating potential growth in the target industry.
Recently, in December 2019, the opening generic version of the blood thinner Eliquis received approval by the U.S. FDA. The drug is anticipated to provide quality treatment alternatives at affordable prices, especially for recurrent AFib patients, by reducing the risk of recurrence.
The device type product segment is estimated to reach USD 5.88 billion by the year 2027 at a CAGR of 14.0% during the forecast period.
Electrophysiology can estimate the electrical activity of the heart while the catheter ablation technique is used to treat arrhythmia of specific types. Electrophysiology is regarded as the most effective method for recurrent episodes of atrial fibrillation after drugs remain ineffective to the patient’s body.
Atrial fibrillation diagnosis includes screening as regular care in elderly patients and patients with other risk factors. Diagnostic testing also includes an ECG or EKG heart’s electrical activity. The presence of advanced software based ECG monitoring devices would improve the quality of treatment for recurrent atrial fibrillation patients.
Key Questions Answered in the Report:
What is the growth rate of the Recurrent Atrial Fibrillation market? What is the anticipated market valuation of Recurrent Atrial Fibrillation industry by 2027?
What are the key growth driving and restraining factors of the Recurrent Atrial Fibrillation market?
Who are the prominent players operating in the market? What are the key strategies adopted by these companies?
What are the key opportunities and growth prospects of the Recurrent Atrial Fibrillation industry over the forecast period?
Which region is expected to show significant growth in the coming years?
Request customization of the report: https://www.emergenresearch.com/request-for-customization/71
Emergen Research have segmented the global Recurrent Atrial Fibrillation Market on the basis of product, application, end-uses, and region:
Product Outlook (Revenue, USD Billion; 2017-2027)
- Device
- Surgical Devices
- Maze Surgery
- Catheter Ablation
- Radiofrequency Catheter Ablation
- Conventional RF Ablation Catheters
- Irrigated-tip RF Ablation Catheters
- Cryoablation
- Microwave Based Catheter Ablation
- Laser Based Catheter Ablation
- Navigational Advanced Mapping Accessories
- Non-Surgical Devices
- Electric Cardioversion
- EP Ablation Catheters
- EP Diagnostic Catheter
- Conventional Diagnostic Catheters
- Fixed Diagnostic Catheters
- Steerable Diagnostic Catheters
- Advanced Diagnostic Catheters
- Mapping and Recording Systems
- Cardiac Monitors or Loop Recorders
- Access Devices
- Left Atrial Appendage and Closure Devices
- Intracardiac Echocardiography (ICE) Systems
- Drugs
- Dabigatran (Pradaxa)
- Rivaroxaban (Xarelto)
- Apixaban (Eliquis)
- Edoxaban (Savaysa)
- Warfarin (Coumadin)
- Others
Application Outlook (Revenue, USD Billion; 2017-2027)
- EP Ablation
- Diagnostic
- Surgical Cardiac
End Users Outlook (Revenue, USD Billion; 2017-2027)
- Hospitals
- Cardiac Centers
- Ambulatory Care Centers
Market Taxonomy:
Chapter 1: Methodology Scope
- Definition and forecast parameters
- Methodology and forecast parameters
- Data Sources
Chapter 2:
Executive Summary
- Business trends
- Regional trends
- Product trends
- End-use trends
Chapter 3:
Industry Insights
- Industry segmentation
- Industry landscape
- Vendor matrix
- Technological and innovation landscape
Chapter 4:
Regional Landscape
Chapter 5:
Company Profile
- Business Overview
- Financial Data
- Product Landscape
- Strategic Outlook
Global Recurrent Atrial Fibrillation Market Geographical Landscape - Synopsis:
The report closely studies the growth trajectory of the global Recurrent Atrial Fibrillation market. It brings to light the global dominance of the leading regional segments, including North America, Asia Pacific, Europe, Latin America, and the Middle East Africa.
The study elaborates on the crucial information pertaining to the regional market share. It simultaneously focuses on the significant details about the growth patterns of each regional market.
Moreover, the report encases an exhaustive geographical study of the market, emphasizing the business growth prospects and market barriers for each of the key market regions.
Read More: https://www.emergenresearch.com/industry-report/recurrent-atrial-fibrillation-market
Related reports:
rfid in healthcare market
nucleic acid isolation and purification market
non-invasive prenatal testing market
in-vitro fertilization market
medical image analytics market
joint reconstruction devices market
precision medicine market
microfluidics market
https://www.google.com.af/url?q=https://www.emergenresearch.com/industry-report/microfluidics-market
About Us:
At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Facebook | LinkdIn | Twitter | Blogs
